any interstate or intrastate telecommunications service. The Commission’s consideration of preemption under section 253 typically begins with the filing of a petition by an aggrieved party. The Commission typically places such petitions on public notice and requests comment by interested parties. The Commission’s decision is based on the public record, generally composed of the petition and comments. The Commission has considered a number of preemption items since the passage of the Telecommunications Act of 1996, and believes it is in the public interest to inform the public of the information necessary for full consideration of the issues likely to be involved in section 253 preemption actions. In order to render a timely and informed decision, the Commission expects petitioners and commenters to provide it with relevant information sufficient to describe the legal regime involved in the controversy and to provide the factual information necessary for a decision. 

Federal Communications Commission.

Marlene H. Dortch,
Secretary, Office of the Secretary, Office of the Managing Director.

* * * * *

February 10, 2015.

This meeting will be closed to the public.

Federal Register Citation of Previous Announcement—80 FR 1030 (January 8, 2015)

This meeting will be continued on February 10, 2015.

PERSON TO CONTACT FOR INFORMATION:
Judith Ingram, Press Officer, Telephone: (202) 694–1220.

Shelley E. Garr,
Deputy Secretary of the Commission.

FEDERAL ELECTRON RETHIRED THIRT INVESTMENT BOARD

Sunshine Act; Notice of Meeting

TIME AND DATE: 8:30 a.m. (Eastern Time) January 26, 2015.

PLACE: 10th Floor Board Meeting Room, 77 K Street NE., Washington, DC 20002.

STATUS: Parts will be open to the public and parts will be closed to the public.

MATTERS TO BE CONSIDERED:
Open to the Public
1. Approval of the Minutes of the December 15, 2014 Board Member Meeting
2. Leadership Development Program
3. Thrift Savings Plan Reports
   a. Monthly Participant Activity Report
   b. Quarterly Investment Policy Report
   c. Legislative Report
   d. Vendor Financials
   e. Audit Status
   f. Budget Review
4. Annual Expense Ratio Review
5. Project Prioritization Overview
6. Enterprise Risk Assessment

Closed to the Public
7. Litigation

CONTACT PERSON FOR MORE INFORMATION:
Kimberly Weaver, Director, Office of External Affairs, (202) 942–1640.

DATE: January 15, 2015.

James Petrick,
General Counsel, Federal Retirement Thrift Investment Board.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Decision to Evaluate a Petition To Designate a Class of Employees From the Lawrence Livermore National Laboratory in Livermore, California, To Be Included in the Special Exposure Cohort

AGENCY: National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention, Department of Health and Human Services.

ACTION: Notice.

SUMMARY: NIOSH gives notice as required by 42 CFR 83.12(e) of a decision to evaluate a petition to designate a class of employees from the Lawrence Livermore National Laboratory in Livermore, California, to be included in the Special Exposure Cohort under the Energy Employees Occupational Illness Compensation Program Act of 2000. The initial proposed definition for the class being evaluated, subject to revision as warranted by the evaluation, is as follows:

Facility: Lawrence Livermore National Laboratory.
Location: Livermore, California.
Job Titles and/or Job Duties: All employees of the Department of Energy, its predecessor agencies, and its contractors and subcontractors who worked in any area.

FOR FURTHER INFORMATION CONTACT:
Stuart L. Hinnefeld, Director, Division of Compensation Analysis and Support, National Institute for Occupational Safety and Health, 1090 Tusculum Avenue, MS C–46, Cincinnati, OH 45226–1938, Telephone 877–222–7570. Information requests can also be submitted by email to DCAS@CDC.GOV.

John Howard,
Director, National Institute for Occupational Safety and Health.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

Bin Kang, Ph.D., Oklahoma Medical Research Foundation: Based on the Respondent’s admission, an assessment conducted by the Oklahoma Medical Research Foundation (OMRF), and additional analysis conducted by ORI in its oversight review, ORI found that Dr. Bin Kang, Postdoctoral Fellow, Immunobiology and Cancer Research Program, OMRF, engaged in research misconduct in research supported by National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), grants AI056129 and AI104057. ORI and OMRF found that Respondent engaged in research misconduct by reporting falsified data in:

• “Asb2 regulates the activity of SCF E3 ubiquitin ligases by antagonizing CAND1-mediated exchange of F-box proteins,” submitted to Molecular Cell on June 26, 2014, which hereafter referred to as the “original Molecular Cell manuscript”